|UCL School of Pharmacy|
|Centre for Paediatric Pharmacy Research|
|Department of Practice & Policy|
|BMA House, Tavistock Square|
|London WC1H 9JP|
|Dr Macey Murray|
|Phone: +44 (0) 20 7874 1535|
|Fax: +44 (0) 20 7387 5693|
|Dr Julie Bennett|
|Phone: +44 (0) 20 7874 1532|
|Fax: +44 (0) 20 7387 5693|
|Ms Yingfen Hsia|
|Phone: +44 (0) 20 7874 1538|
|Fax: +44 (0) 20 7387 5693|
Description of organization
The School of Pharmacy (SoP) is the only institution in the UK entirely devoted to teaching and research in pharmacy and pharmaceutical sciences. It has a research track record of international excellence and attracts post‐graduate and post‐doctorate researchers from all over the world. The Centre for Paediatric Pharmacy Research (CPPR) was established in The School of Pharmacy in April 2002 in collaboration with the Institute of Child Health and Great Ormond Street Hospital for Children. The aim of the Centre is to improve paediatric medicines and in particular, their quality, safety, efficacy and associated ethical policies. In addition, the specialist resources of universities and hospitals nationwide are utilized collaboratively to provide a focus for the training of health care professionals in the optimum use of medicines for children. It is the first centre of its kind to be established in the UK.
The Centre has comprehensive expertise in paediatric pharmacoepidemiology and drug safety including the conduct of large scale and multinational epidemiological studies using longitudinal databases. It has been conducting paediatric medicines research since it was established in 2002. The Centre has been involved in many national and international collaborations such as the EU‐commissioned FP6 “Task Force in Europe for Drug Development in the Young” (TEDDY), FP7 “Paediatric European Risperidone Studies” (PERS), and FP7 “Global Research in Paediatrics” (GRIP). The Centre has recently successfully obtained approval from the EMA on the Paediatric Investigation Plan (PIP). In September 2011, the Centre was involved in obtaining the first Paediatric Use Marketing Authorisation (PUMA) for a product.
Profile of staff members
Dr. Macey Murray is a Senior Research Fellow in the CPPR. Dr. Murray has seven years’ experience of working in phase I‐III clinical trials, from their inception to the management of data for statistical analysis. She has extensive experience in post‐marketing surveillance of psychotropic drugs in children, and has expertise in using electronic health record databases such as the UK General Practice Research Database (GPRD), The Health Improvement Network (THIN) and IMS Disease Analyzer (IMS DA).
Dr. Julie Bennett is the EU Project Manager at the CPPR. She has extensive experience in administration, and is responsible for the project management of ADDUCE.
Ms. Yingfen Hsia is a Research Fellow in the CPPR. Ms. Hsia has many years of experience using primary care databases such as the GPRD and IMS DA to conduct studies in children and adolescents.
Prof. Ian Wong is a visiting Professor and founding Director of the Centre. He is now Head of the Department of Pharmacology and Pharmacy at Hong Kong University. Until June 2011, he was the Chair of the Pharmacy and Pharmacology Clinical Study Group of the UK Medicines for Children Research Network (MCRN) and Chair of the Long‐term Effects of Psychotropic Medication in the Children Research Group of the Mental Health Research Network. Prof. Wong has published over 80 research papers. He was also a member of the UK ADHD NICE guideline group and has also worked with pharmaceutical companies to conduct clinical trials studies for paediatric licensing applications.
Main tasks in the project:
SoP will be significantly involved in WP2 (Retrospective Data Acquisition) and WP3 (Prospective Study).
The fifth ADDUCE Newsletter is now available!
Here, you can read about the finalisation of the project,
the European Medicines Agency and General Assembly meetings
and the dissemination of the results!
The fourth ADDUCE Newsletter is available!
In this newsletter, you can find some information on the final recruitment status of the 2 main studies:
- the prospective open-label methylphenidate pharmacovigilance study
- the long-term cardiascular effects of methylphenidate use
Also, you can read about the future plans of the project!
More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before!
Did you participate in the ADDUCE studies and are you curious about the latest news on the project?
Here you can find some information!
News for children, April 2015
News for adolescents, April 2015
News for parents, April 2015
The third ADDUCE Newsletter is available!
- the prospective open-label methylphenidate pharmacovigilance study: recruitment status and spin-
- the long-term cardiovascular effects of methylphenidate use: study design and participation
and much more in the ADDUCE Newsletter 3, March 2015
WP3: prospective open-label methylphenidate
- WP8: long-term cardiovascular effects of methylphenidate use
and much more in the ADDUCE Newsletter 2, February 2013
16 - 19 OCTOBER 2016:
4rd EUNETHYDIS International Conference on ADHD, Berlin - Germany
from basis neuroscience to optimised clinical care
17 & 18 APRIL 2016:
ADDUCE Consortium meeting, London - UK
28 - 31 MAY 2015:
5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland
20 & 21 APRIL 2015:
ADDUCE Consortium meeting, Salina - Italy
21 - 24 MAY 2014:
3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders
19 & 20 MAY 2014:
ADDUCE Consortium meeting, Istanbul - Turkey
3 - 6 OCTOBER 2013:
23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders
6 - 9 JUNE 2013:
4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy
4 & 5 JUNE 2013:
ADDUCE Consortium meeting, Milan - Italy
6 & 7 JUNE 2012:
ADDUCE Consortium meeting, Cagliari - Italy
23 MAY 2012:
2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain